Most reported reactions to mRNA Covid-19 vaccination were mild and transient, a large observational US study finds.
Collating reports from one passive (Vaccine Adverse Event Reporting System) and one active (v-safe) surveillance system, researchers at the US Centers for Disease Control and Prevention assessed reactogenicity, health impacts and adverse events following more than 298 million mRNA COVID-19 vaccine doses (Pfizer-BioNTech and Moderna) given during the first six months of the US vaccination programme.
VAERS processed 340,522 reports with 92.1% classified as non-serious, including headache (20% of total reports), fatigue (17%), fever (16%), chills (16%) and pain (15%).
A further 6.6% of side effects were registered as serious, with the most common being shortness of breath (4,175/340,522 or 15%).
Of the adverse events reported to VAERS during the study period, approximately 4500 (1.3%) were deaths, with more than 80% of these among people aged 60 years and over.
Covid-19 vaccines were authorised under emergency use, meaning healthcare providers were required to report all deaths following vaccination, regardless of the potential direct association, the researchers noted.
'Similar to general mortality in the adult population, reporting rates for deaths in this analysis increased with increasing age,' they wrote in The Lancet Infectious Diseases.
'We found no unusual patterns in cause of death among the death reports received.'
More than half of the almost 8 million v-safe participants self-reported local and systemic reactogenicity, with reactions more likely after the second dose of either vaccine compared with the first dose.
Side effects were most frequently reported the day after vaccination and were nearly all mild, with the most common being fatigue (34% after dose one, 56% after dose two), headache (27% after dose one, 46% after dose two), and injection site pain (66% after dose one, 69% after dose two). There were more v-safe reports of being unable to work, perform normal activities, or seeking medical care after dose two. Less than 1% of participants reported seeking medical care after either vaccine dose.
'Female participants and individuals younger than 65 years reported adverse events and reactions more frequently than male participants and those aged 65 years and older respectively,' the researchers added.
Female participants were known to have more vigorous antibody responses to certain vaccine and tended to report more severe local and systemic reactions to influenza vaccine, compared with male recipients, they noted.
Study limitations include the VAERS system relying on spontaneous reporting meaning it was not representative of the entire population and people without a smartphone being unable to participate in the v-safe system. An accompanying editorial called the data reassuring, highlighting that no unusual patterns emerged in causes of death or serious adverse events among VAERS reports.
'For adverse events of special interest, it is reassuring that there were no unexpected signals other than myopericarditis and anaphylaxis, already known to be associated with mRNA vaccines,' the editorial said.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.